このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

再発リスクが高い限局性乳がん患者における補助療法として使用される細胞周期阻害剤への遵守状況の評価 (AdheRA)

2026年9月29日 更新者:University Hospital, Grenoble

高再発リスクの限局性乳癌患者における補助療法として使用される細胞周期阻害薬へのアドヒアランスの評価

Hormone receptor-positive (HR+) breast cancers represent the most common histological subtype of breast cancer, accounting for approximately 75% of cases, regardless of HER2 (human epidermal growth factor receptor 2) status (1). Adjuvant endocrine therapy (ET), including tamoxifen and aromatase inhibitors (AIs), is an effective pharmacological treatment for improving the prognosis of HR+ breast cancer, reducing the risk of recurrence by up to 50% (2-3-4-6). Despite its proven prognostic benefit, the full potential of endocrine therapy is not realized due to patient non-adherence (i.e., failure to comply with prescribed treatment). Adjuvant endocrine therapy is generally prescribed for a duration of 5 to 10 years. However, up to 40% of patients discontinue treatment prematurely, and 30% take the medication less frequently than prescribed. Poor adherence and low treatment persistence carry a substantial mortality burden: non-adherence is associated with a 49% increase in all-cause mortality. A retrospective analysis of a large database including more than 8,700 patients showed a 10-year survival rate of 80.7% among women who continued treatment, compared with 73.6% among those who discontinued adjuvant therapy prematurely (p < 0.001). Among patients who continued treatment, the survival rate was 82% in those who were fully adherent, versus 78% in those who were only partially adherent (7-16).

The literature has documented a wide range of risk factors associated with non-adherence to or discontinuation of long-term adjuvant endocrine therapy. Treatment-related adverse effects, including hot flashes, joint stiffness, and sexual dysfunction, are common and may lead to treatment discontinuation. Fear of side effects may also prevent some patients from initiating or maintaining endocrine therapy. Others may not be fully convinced of the necessity of adjuvant endocrine therapy, particularly in the absence of overt signs of cancer. In addition, supportive care required to manage side effects is often inadequately reimbursed, making low income-combined with broader socioeconomic factors-a potential barrier to optimal adherence. Some patients may also experience difficulties remembering to take their medication regularly. The relative importance and contribution of these factors to non-adherence may evolve over time. Other factors may also play a role, including sociodemographic characteristics (low income, living alone, or unemployment).

Nevertheless, a residual risk of recurrence persists after five years of well-conducted standard endocrine therapy, extending up to two decades after diagnosis, particularly in patients with early-stage breast cancer stages II and III. In this higher-risk population, two phase III trials, monarchE and NATALEE, have recently evaluated the addition of a cell cycle inhibitor (CDK4/6 inhibitor) to standard adjuvant endocrine therapy and reported positive results with a reduction in the risk of relapse.

In the NATALEE trial, quality of life was assessed in all patients in the ribociclib plus aromatase inhibitor group (n = 2,549) versus the aromatase inhibitor alone group (n = 2,552). Mean scores did not differ significantly from baseline for any of the analyzed domains. Similarly, no significant change from baseline was observed in either treatment group.

However, it is important to note that 33.8% of patients discontinued ribociclib and 20% discontinued both endocrine therapy and ribociclib in the NATALEE trial, which is consistent with data from the literature.

In the monarchE trial, 16.6% of patients discontinued abemaciclib, and 6% discontinued both abemaciclib and endocrine therapy, while only 0.8% discontinued endocrine therapy in the control group. These findings are not consistent with previously published data.

To our knowledge, no real-world study has evaluated CDK4/6 inhibitors in combination with endocrine therapy in the adjuvant treatment of HR+/HER2-negative breast cancer.

AdheRA is a prospective multicenter cohort study of patients with early-stage HR+/HER2-negative breast cancer at high risk of recurrence, eligible for a combination of endocrine therapy and a CDK4/6 inhibitor such as abemaciclib or ribociclib in the adjuvant setting, aiming to assess treatment adherence and the reasons for non-adherence.

調査の概要

研究の種類

観察的

入学 (推定)

81

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Patients will be selected from those with localized, high-risk, hormone receptor-positive, HER2-negative breast cancer who are treated at one of the two participating centers and receive adjuvant therapy between 2023 and 2028, and who are eligible for treatment with CDK4/6 inhibitors.

Patients will be seen in dedicated consultations, according to international recommendations, at least every six months, to assess treatment adherence, tolerability, and risk of recurrence. Recruitment will therefore take place directly during these consultations.

All patients for whom an indication for iCDK4/6 therapy is established will be eligible to participate in the study. This indication is determined during multidisciplinary tumor board meetings, which are standard practice in the patient care pathway.

The end of the inclusion period has been arbitrarily set five years later, in order to obtain a sufficient number of patients.

説明

Inclusion Criteria

  • Male or female patients aged ≥18 years.
  • Operable invasive breast carcinoma of no special type, hormone receptor-positive / HER2-negative (estrogen receptor expression >10% with or without progesterone receptor expression >10%; HER2-negative defined as score 0, 1+, or 2+ non-amplified).
  • M0 disease according to the TNM 2018 classification.
  • Having undergone curative surgery of the primary breast tumor.
  • Having received adjuvant radiotherapy, if indicated.
  • Indication for combined adjuvant endocrine therapy and iCDK4/6 therapy validated during a multidisciplinary tumor board meeting.
  • Initiation of adjuvant endocrine therapy combined with a CDK4/6 inhibitor between June 2023 and June 2028.
  • No objection to participation in the study.
  • Affiliation with the national health insurance system.

Non-Inclusion Criteria

  • Medical, geographical, sociological, psychological, or legal conditions that could prevent the patient from completing the study or from providing informed non-opposition.
  • Locally advanced, non-operable disease or metastatic disease not amenable to curative-intent treatment

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
The primary objective of this study is to evaluate adherence to iCDK4/6 treatment in patients with localized hormone receptor-positive breast cancer at high risk of recurrence, within a real-world setting.
時間枠:Early discontinuation is defined as cessation of treatment prior to 20 months (of a planned 24-month duration) for abemaciclib or prior to 30 months (of a planned 36-month duration) for ribociclib.

The percentage of early discontinuation of iCDK4/6 therapy will be assessed. Early discontinuation is defined as cessation of treatment prior to 20 months (of a planned 24-month duration) for abemaciclib or prior to 30 months (of a planned 36-month duration) for ribociclib.

Early discontinuation is defined as cessation of treatment prior to 20 months (of a planned 24-month duration) for abemaciclib or prior to 30 months (of a planned 36-month duration) for ribociclib.

二次結果の測定

結果測定
メジャーの説明
時間枠
The objective is to estimate the proportion of patients who did not initiate iCDK4/6 therapy.
時間枠:From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib

The proportion of patients eligible for iCDK4/6 therapy who, in real-world clinical practice, did not initiate treatment.

From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib
To estimate the mean treatment completion rate for iCDK4/6 therapy and endocrine therapy.
時間枠:From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib

2a. Percentage of completion of iCDK4/6 therapy (over the planned 2- or 3-year duration).

2b. Percentage of completion of endocrine therapy (over the planned 5-year duration, minimum required).

2c. Median duration of endocrine therapy and iCDK4/6 therapy.

From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib
To estimate the proportion of dose modifications and to describe the reasons for these modifications.
時間枠:From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib.

3a. Percentage of patients who experienced a dose reduction of iCDK4/6 therapy. 3b. Assessment of the reasons for iCDK4/6 dose reductions. 3c. Assessment of the reasons for iCDK4/6 treatment discontinuation.

From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib.
To describe risk factors associated with non-adherence.
時間枠:From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib

Collection and description of factors associated with non-adherence, including adverse events, physical activity, and sociodemographic factors.

From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib
To evaluate invasive disease-free survival.
時間枠:From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib

Evaluation of invasive disease-free survival (iDFS).

From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Emmanuelle JACQUET、University Hospital, Grenoble

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年5月26日

一次修了 (推定)

2031年4月1日

研究の完了 (推定)

2031年12月1日

試験登録日

最初に提出

2026年1月26日

QC基準を満たした最初の提出物

2026年2月26日

最初の投稿 (実際)

2026年3月2日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月2日

QC基準を満たした最後の更新が送信されました

2026年9月29日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 38RC25.0403
  • 2025-A02911-48 (その他の識別子:ID RCB)

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する